MedTrace Logo

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04466917 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-07-03

No results posted yet for this study

Summary

The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

ABP 215

ABP 215 will be administered at a dose of 15 mg/kg IV

DRUG

Bevacizumab

Bevacizumab will be administered at a dose of 15 mg/kg IV

DRUG

Paclitaxel

Paclitaxel will be administered 175 mg/m2 IV

DRUG

Carboplatin

Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2022-11-13
Completion
2022-11-13
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466917 on ClinicalTrials.gov